Detailed price information for Bright Minds Biosciences Inc (DRUG-Q) from The Globe and Mail including charting and trades.

SAN FRANCISCO, CA--January 2, 2019--As early as 3 months of age, infants with a severe form of epilepsy called Dravet syndrome start having convulsive seizures, during which their arms and legs jerk ...

A recent study characterizes silent seizures in a mouse model of Dravet syndrome and identifies a new brain area that could be targeted to stop them. As early as 3 months of age, infants with a severe ...

Atypical, because they last longer--10 to 30 seconds on average--than those seen in children with typical absence epilepsy. Absence, because the patients appear as if they are mentally absent during ...

Despite its rarity, NCSE is found in a wide variety of situations in childhood, some of which are described in detail below. For the sake of clarity, these conditions can be grouped in three separate ...

New Treatment Option for Seizures Associated with Lennox-Gastaut Syndrome WOODCLIFF LAKE, N.J., Nov. 14 /PRNewswire/ -- Eisai Corporation of North America announced today that the U.S. Food and Drug ...

BTIG initiated coverage on Bright Minds Biosciences Inc. (NASDAQ:DRUG), a clinical-stage company focused on neurological and psychiatric disorders. Investment in Bright Minds is based on the ...

Researchers aimed to identify the characteristics, treatment pathways, and outcomes associated with epilepsy with eyelid myoclonia (EEM). Epilepsy with eyelid myoclonia (EEM) is a rare and ...